Venture&Growth
Location
Murray Hill (NJ), USA
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
FlowCardia is a medical device company marketing catheters that reopen obstructed arteries in the legs, which can avoid amputation. Its lead product, the CROSSER™, uses high-frequency vibration to penetrate hard arterial blockages.
After Gilde led a large institutional financing round of growth capital, the company built a marketing and sales organization, expanded its product portfolio and developed into a high-growth, revenue-generating business. FlowCardia was acquired by C. R. Bard, Inc. (NYSE: BCR) in 2010. It was located in Sunnyvale, California.
More Flowcardia news
FlowCardia, Inc. Initiates CENTRAL Study Enrollment
FlowCardia, Inc. expands treatment options for patients with chronic total occlusion
FlowCardia, Inc. Launches FlowMate™ Injector to Optimize Performance
FlowCardia, Inc. Appoints Deborah DeFilippo CFO
Venture&Growth
Acacia Pharma
Belgian Therapeutics company commercializing supportive care products to treat side effects of medical procedures.
Venture&Growth
CVRx
US-based MedTech company focused on treatment of heart failure applying neurostimulation.
Venture&Growth
Argá Medtech
Argá Medtech is developing the next generation non-thermal cardiac ablation system. The system for treating atrial fibrillation (AF) uses pulsed field ablation, the energy modality of choice because of a superior safety profile. Arga has a novel catheter design and unique
